N-acetyltransferase 2 genotype modification of active cigarette smoking on breast cancer risk among hispanic and non-hispanic white women

Toxicological Sciences

Volumn 112, Issue 1, 2009, Pages 211-220

  Baumgartner, Kathy B ^a   Schlierf, Thomas J ^b   Yang, Dongyan ^a   Doll, Mark A ^b   Hein, David W ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Acetylator; Arylamine carcinogens; Breast cancer; Cigarette smoking; Hispanic; N acetyltransferase 2; Phenotype

Indexed keywords

ACYLTRANSFERASE; ACYLTRANSFERASE 2; AROMATIC AMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; ETHNICITY; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PHENOTYPE; POPULATION RESEARCH; RNA TRANSLATION; UNITED STATES;

ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; RISK FACTORS; SMOKING; TOBACCO;

EID: 71049183469     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp199     Document Type: Article

References (56)

1. Alberg, A. J., Daudt, A., Huang, H.-Y., Hoffman, S. C., Comstock, G. W., Helzlsouer, K. J., Strickland, P. T., and Bell, D. A. (2004). N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev. 28, 187-193.
2. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemoto, T., Gillenwater, K. A., et al. (1996). Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276, 1494-1501.
3. Ambrosone, C. B., Kropp, S., Yang, J., Yao, S., Shields, P. G., and Chang-Claude, J. (2008). Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: Pooled analysis and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 17, 15-26.
4. Baumgartner, K. B., Annegers, J. F., McPherson, R. S., Frankowski, R. F., Gilliland, F. D., and Samet, J. M. (2002). Is alcohol intake associated with breast cancer in Hispanic women? The New Mexico Women's Health Study. Ethn. Dis. 12, 460-469.
5. Bendaly, J., Doll, M. A., Millner, L. M., Metry, K. J., Smith, N. B., Pierce, W. M., and Hein, D. W. (2009). Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations. Mut. Res. Online publication August 12, 2009, Doi: 10.1016/j.mrfmmm.2009.08.003.
6. Buechley, R. W. (1976). In Generally Useful Ethnic Search System: GUESS. Cancer Research and Treatment Center, The University of New Mexico, Albuquerque, NW.
7. Chang-Claude, J., Kropp, S., Jager, B., Bartsch, H., and Risch, A. (2002). Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 698-704.
8. Deitz, A. C., Rothman, N., Rebbeck, T. R., Hayes, R. B., Chow, W. H., Zheng, W., Hein, D. W., and Garcia-Closas, M. (2004). Impact of misclassification in genotype-exposure interaction studies: Example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1543-1546.
9. Delfino, R. J., Smith, C., West, J. G., Lin, H. J., White, E., Liao, S. Y., Gim, J. S., Ma, H. L., Butler, J., and Anton-Culver, H. (2000). Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 10, 461-469.
10. Doll, M. A., and Hein, D. W. (2001). Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal. Biochem. 288, 106-108.
11. Egan, K. M., Newcomb, P. A., Titus-Ernstoff, L., Trentham-Dietz, A., Mignone, L. I., Farin, F., and Hunter, D. J. (2003). Association of NAT2 and smoking in relation to breast cancer incidence in a population-based case-control study (United States). Cancer Causes Control 14 43-51.
12. el-Bayoumy, K. (1992). Environmental carcinogens that may be involved in human breast cancer etiology. Chem. Res. Toxicol. 5, 585-590.
13. Faraglia, B., Chen, S. Y., Gammon, M. D., Zhang, Y., Teitelbaum, S. L., Neugut, A. I., Ahsan, H., Garbowski, G. C., Hibshoosh, H., Lin, D., et al. (2003). Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: The influence of tobacco smoke. Carcinogenesis 24, 719-725.
14. Firozi, P. F., Bondy, M. L., Sahin, A. A., Chang, P., Lukmanji, F., Singletary, E. S., Hassan, M. M., and Li, D. (2002). Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23, 301-306.
15. Fretland, A. J., Leff, M. A., Doll, M. A., and Hein, D. W. (2001). Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11, 207-215.
16. Garcia-Martin, E. (2008). Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr. Drug Metab. 9, 487-497.
17. Gram, I. T., Braaten, T., Terry, P. D., Sasco, A. J., Adami, H. O., Lund, E., and Weiderpass, E. (2005). Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiol. Biomarkers Prev. 14, 61-66.
18. Hein, D. W. (2002). Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507, 65-77.
19. Hein, D. W. (2006). N-acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25, 1649-1658.
20. Hein, D. W. (2009). N-acetyltransferase SNPs: Emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin. Drug Metab. Toxicol. 5, 353-366.
21. Hein, D. W., Doll, M. A., Rustan, T. D., and Ferguson, R. J. (1995). Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55, 3531-3536.
22. Hein, D. W., Ferguson, R. J., Doll, M. A., Rustan, T. D., and Gray, K. (1994). Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet. 3, 729-734.
23. Howard, C. A., Samet, J. M., Buechley, R. W., Schrag, S. D., and Key, C. R. (1983). Survey research in New Mexico Hispanics: Some methodological issues. Am. J. Epidemiol. 117, 27-34.
24. Huang, C. S., Chern, H. D., Shen, C. Y., Hsu, S. M., and Chang, K. J. (1999). Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer 82, 175-179.
25. Hunter, D. J., Hankinson, S. E., Hough, H., Gertig, D. M., Garcia-Closas, M., Spiegelman, D., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E., et al. (1997). A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 18, 2127-2132.
26. Jemal, A., Center, M. M., Ward, E., and Thun, M. J. (2009). Cancer occurrence. Methods Mol. Biol. 471, 3-29.
27. Khuder, S. A., Mutgi, A. B., and Nugent, S. (2001). Smoking and breast cancer: A meta-analysis. Rev. Environ. Health 16, 253-261.
28. Krajinovic, M., Ghadirian, P., Richer, C., Sinnett, H., Gandini, S., Perret, C., Lacroix, A., Labuda, D., and Sinnett, D. (2001). Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizing enzymes and gene-environment interactions. Int. J. Cancer 92, 220-225.
29. Lash, T. L., Bradbury, B. D., Wilk, J. B., and Aschengrau, A. (2005). A case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology. Breast Cancer Res. 7, R385-R93.
30. Lin, Y., Kikuchi, S., Tamakoshi, K., Wakai, K., Kondo, T., Niwa, Y., Yatsuya, H., Nishio, K., Suzuki, S., Tokudome, S., et al. (2008). Active smoking, passive smoking, and breast cancer risk: Findings from the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. J. Epidemiol. 18, 77-83.
31. Lissowska, J., Brinton, L. A., Zatonski, W., Blair, A., Bardin-Mikolajczak, A., Peplonska, B., Sherman, M. E., Szeszenia-Dabrowska, N., Chanock, S., and Garcia-Closas, M. (2006). Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int. J. Cancer 119, 1961-1969.
32. Millikan, R. C., Pittman, G. S., Newman, B., Tse, C. K., Selmin, O., Rockhill, B., Savitz, D., Moorman, P. G., and Bell, D. A. (1998). Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 7, 371-378.
33. Morabia, A., Bernstein, M. S., Bouchardy, I., Kurtz, J., and Morris, M. A. (2000). Breast cancer and active and passive smoking: The role of the N-acetyltransferase 2 genotype. Am. J. Epidemiol. 152, 226-232.
34. Mueck, A. O., and Seeger, H. (2005). Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc Hematol. Agents 3, 45-54.
35. Nagata, C., Mizoue, T., Tanaka, K., Tsuji, I., Wakai, K., Inoue, M., and Tsugane, S. (2006). Tobacco smoking and breast cancer risk: An evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn. J. Clin. Oncol. 36, 387-394.
36. Ochs-Balcom, H. M., Wiesner, G., and Elston, R. C. (2007). A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am. J. Epidemiol. 166, 246-254.
37. Perera, F. P., Estabrook, A., Hewer, A., Channing, K., Rundle, A., Mooney, L. A., Whyatt, R., and Phillips, D. H. (1995). Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol. Biomarkers Prev. 4, 233-238.
38. Phillips, D. H., and Garte, S. (2008). Smoking and breast cancer: Is there really a link? Cancer Epidemiol. Biomarkers Prev. 17, 1-2.
39. Reynolds, P., Hurley, S., Goldberg, D. E., Anton-Culver, H., Bernstein, L., Deapen, D., Horn-Ross, P. L., Peel, D., Pinder, R., Ross, R. K., et al. (2004). Active smoking, household passive smoking, and breast cancer: Evidence from the California Teachers Study. J. Natl. Cancer Inst. 96, 29-37.
40. Rowland, M. L., and Forthofer, R. N. (1993). Investigation of nonresponse bias: Hispanic Health and Nutrition Examination Survey. Vital Health Stat. 2, 1-75.
41. Sillanpaa, P., Hirvonen, A., Kataja, V., Eskelinen,M., Kosma, V.-M., Uusitupa,M., Vainio, H., and Mitrunen, K. (2005). NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int. J. Cancer 114, 579-584.
42. Slattery, M. L., Curtin, K., Giuliano, A. R., Sweeney, C., Baumgartner, R., Edwards, S., Wolff, R. K., Baumgartner, K. B., and Byers, T. (2008). Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res. Treat. 109, 101-111.
43. Slattery, M. L., Curtin, K., Sweeney, C., Wolff, R. K., Baumgartner, R. N., Baumgartner, K. B., Giuliano, A. R., Byers, T., and Slattery, M. L. (2007). Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res. Treat. 102, 85-101.
44. Slattery, M. L., Sweeney, C., Edwards, S., Herrick, J., Murtaugh, M., Baumgartner, K., Guiliano, A., and Byers, T. (2006). Physical activity patterns and obesity in Hispanic and non-Hispanic white women. Med. Sci. Sports Exerc. 38, 33-41.
45. Sweeney, C., Edwards, S. L., Baumgartner, K. B., Herrick, J. S., Palmer, L. E., Murtaugh, M. A., Stroup, A., and Slattery, M. L. (2007). Recruiting Hispanic women for a population-based study: Validity of surname search and characteristics of nonparticipants. Am. J. Epidemiol. 166, 1210-1219.
46. Tansavatdi, K., McClain, B., and Herrington, D. M. (2004). The effects of smoking on estradiol metabolism. Minerva Ginecol. 56, 105-114.
47. Terry, P. D., and Rohan, T. E. (2002). Cigarette smoking and the risk of breast cancer in women: A review of the literature. Cancer Epidemiol. Biomarkers Prev. 11, 953-971.
48. U.S. Department of Health and Human Services. (2004). The Health Consequences of Smoking: A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
49. van der Hel, O. L., Peeters, P. H. M., Hein, D. W., Doll, M. A., Grobbee, D. E., Kromhout, D., and Bueno de Mesquita, H. B. (2003). NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13, 399-407.
50. Wacholder, S., Rothman, N., and Caporaso, N. (2000). Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J. Natl. Cancer Inst. 92, 1151-1158.
51. Walraven, J. M., Zang, Y., Trent, J. O., and Hein, D. W. (2008). Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr. Drug Metab. 9, 471-486.
52. Wang, C., Baumgartner, R. N., Yang, D., Slattery, M. L., Murtaugh, M. A., Byers, T., Hines, L. M., Giuliano, A. R., and Baumgartner, K. B. (2009). No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. Breast Cancer Res. Treat. 114, 137-145.
53. Wold, K. S., Byers, T., Crane, L. A., and Ahnen, D. (2005). What do cancer survivors believe causes cancer? (United States). Cancer Causes Control 16, 115-123.
54. Word, D. L., and Perkins, R. C. (1996). Building a Spanish surname list for the 1990's-A new approach to an old problem. Technical Working Paper No. 13, pp. 1-25. Population Division, U.S. Bureau of the Census, Washington, DC.
55. Zang, Y., Doll, M. A., Zhao, S., States, J. C., and Hein, D. W. (2007). Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28 1665-1671.
56. Zang, Y., Zhao, S., Doll, M. A., States, J. C., and Hein, D. W. (2004). The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14, 717-723.